[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]

Gan To Kagaku Ryoho. 1998 Feb;25(3):385-90.
[Article in Japanese]

Abstract

Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor. ICE therapy was administered in doses of Ifosfamide 1,800 mg/m2 x 5, Carboplatin 400 mg/m2 x 2 and Etoposide 100 mg/m2 x 5. A total of 30 courses were administered. Two cases of osteosarcoma had a stable disease (range, 3-9 months) and 2 cases of brain tumor had a complete response by magnetic resonance imaging. Moderate or severe toxicity evaluated on a per course basis included: neutropenia 83%, thrombocytopenia 93%, fever 30%, hepatotoxicity 3%, and hemorrhagic cystitis 3%. The median time to hematologic recovery was 20 days. ICE therapy is highly effective for the treatment of refractory or recurrent solid tumors with acceptable toxicity.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / pathology
  • Brain Neoplasms / drug therapy*
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Child
  • Drug Administration Schedule
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Female
  • Fever / chemically induced
  • Humans
  • Ifosfamide / administration & dosage
  • Ifosfamide / adverse effects
  • Lung Neoplasms / secondary
  • Male
  • Neoplasm Recurrence, Local / drug therapy
  • Neutropenia / chemically induced
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / secondary
  • Pilot Projects
  • Thrombocytopenia / chemically induced

Substances

  • Etoposide
  • Carboplatin
  • Ifosfamide

Supplementary concepts

  • ICE protocol 3